ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2020

Feb 27, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2020-02-25

Reporting Person: Myszkowski Kenneth Allen (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-25	Common Stock	M	12000	$9.90	Acquired	396223	Direct
2020-02-25	Common Stock	M	2000	$5.19	Acquired	398223	Direct
2020-02-25	Common Stock	M	6495	$14.54	Acquired	404718	Direct
2020-02-25	Common Stock	M	12116	$7.75	Acquired	416834	Direct
2020-02-25	Common Stock	M	10834	$6.15	Acquired	427668	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-25	Stock Option (right to buy)	$9.90	M	12000	Disposed	2020-08-16	Common Stock (12000)	Direct
2020-02-25	Stock Option (right to buy)	$5.19	M	2000	Disposed	2022-02-16	Common Stock (2000)	Direct
2020-02-25	Stock Option (right to buy)	$14.54	M	6495	Disposed	2024-02-06	Common Stock (6495)	Direct
2020-02-25	Stock Option (right to buy)	$7.75	M	12116	Disposed	2025-03-06	Common Stock (12116)	Direct
2020-02-25	Stock Option (right to buy)	$6.15	M	10834	Disposed	2026-01-01	Common Stock (10834)	Direct

Footnotes

F1: Represents the first vesting date. Option vested over four years from date of grant.